Adapted from Wolf P.et al. Stroke. 1991.
Example
Adapted from Marini C.et al. Stroke. 2005.
AF: atrial fibrillation; NVAF: nonvalvular atrial fibrillation; VTE: venous thromboembolism.
References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Taggar J, Marin F, Lip G. Mortality in patients with atrial fibrillation: improving or not?. EP Europace. 2008;10(4):389-390
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988. 5. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115-1119. 6. Steinberg BA. How I use anticoagulation in atrial fibrillation. Blood. 2016;128(25):2891-2898. 7. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118-123.
|
Click here for Eliquis® 2.5mg Prescribing Information Click here for Eliquis® 5mg Prescribing Information |
 HF0098OA451/122022 Invalidation Date : 21/08/2024 |
recommendations